Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/wiley/does-consumer-demand-pull-scientifically-novel-drug-innovation-pVx8Ruhukj
References (63)
-
A. Chandra, Craig Garthwaite, A. Stern (2017)
Characterizing the Drug Development Pipeline for Precision MedicinesPharmSciRN: Genomic & Precision Medicine (Sub-Topic)
-
C. Anderson, Ying Zhang (2010)
Security market reaction to FDA fast track designations.Journal of health care finance, 37 2
-
Oliver Mouzon, P. Dubois, Fiona Morton, P. Seabright (2011)
Market Size and Pharmaceutical InnovationHealth Economics eJournal
-
L. Fleming (2001)
Recombinant Uncertainty in Technological Search, 47
-
M. Kremer, R. Glennerster (2004)
Strong Medicine: Creating Incentives for Pharmaceutical Research on Neglected Diseases -
R. Cerda (2007)
Endogenous innovations in the pharmaceutical industryJournal of Evolutionary Economics, 17
-
Melanie Senior (2013)
Drugs with breakthrough status charm investorsNature Biotechnology, 31
-
G.P. Pisano (2006)
Science Business: The Promise, the Reality, and the Future of Biotech -
D. Strumsky, J. Lobo (2015)
Identifying the sources of technological novelty in the process of inventionResearch Policy, 44
-
(2000)
Making Sense of Drug Prices -
J. DiMasi, Lanna Feldman, A. Seckler, A. Wilson (2010)
Trends in Risks Associated With New Drug Development: Success Rates for Investigational DrugsClinical Pharmacology & Therapeutics, 87
-
H. Grabowski, J. Vernon (1994)
Returns to R&D on new drug introductions in the 1980s.Journal of health economics, 13 4
-
P. Doshi, Kay Dickersin, Kay Dickersin, D. Healy, S. Vedula, T. Jefferson (2013)
Restoring invisible and abandoned trials: a call for people to publish the findingsThe BMJ, 346
-
(2011)
Advancing Regulatory Science at FDA -
Dennis Verhoeven, Jurriën Bakker, R. Veugelers (2015)
Measuring Technological Novelty with Patent-Based IndicatorsInnovation Measurement & Indicators eJournal
-
M.A. Johnson, G.M. Maggiora (1990)
Concepts and Applications of Molecular Similarity -
G. McArthur, P. Chapman, C. Robert, J. Larkin, J. Haanen, R. Dummer, A. Ribas, D. Hogg, O. Hamid, P. Ascierto, C. Garbe, A. Testori, M. Maio, P. Lorigan, C. Lebbé, T. Jouary, D. Schadendorf, S. O'Day, J. Kirkwood, A. Eggermont, B. Dréno, J. Sosman, K. Flaherty, M. Yin, I. Caro, Suzanne Cheng, K. Trunzer, A. Hauschild (2014)
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.The Lancet. Oncology, 15 3
-
Chi Wong, K. Siah, A. Lo (2018)
Estimation of clinical trial success rates and related parametersBiostatistics (Oxford, England), 20
-
Amy Finkelstein (2004)
Static and Dynamic Effects of Health Policy: Evidence from the Vaccine IndustryQuarterly Journal of Economics, 119
-
David Dranove, Craig Garthwaite, Manuel Hermosilla (2014)
Pharmaceutical Profits and the Social Value of InnovationSustainable Technology eJournal
-
R. Kneller (2010)
The importance of new companies for drug discovery: origins of a decade of new drugsNature Reviews Drug Discovery, 9
-
D. Acemoglu, Joshua Linn (2003)
Market Size in Innovation: Theory and Evidence from the Pharmaceutical IndustryMIT Economics Department Working Paper Series
-
T. Hara (2003)
Innovation in the Pharmaceutical Industry: The Process of Drug Discovery and Development -
B. Munos, W. Chin (2011)
How to Revive Breakthrough Innovation in the Pharmaceutical IndustryScience Translational Medicine, 3
-
Rosa Abrantes-Metz, C. Adams, Albert Metz (2004)
Pharmaceutical Development Phases: A Duration AnalysisIO: Productivity
-
F. Lichtenberg, Shawn Sun (2007)
The impact of Medicare Part D on prescription drug use by the elderly.Health affairs, 26 6
-
L. Fleming (2001)
Special Issue on Design and Development: Recombinant Uncertainty in Technological SearchManag. Sci., 47
-
Jian Wang, R. Veugelers, Paula Stephan (2015)
Bias Against Novelty in Science: A Cautionary Tale for Users of Bibliometric IndicatorsEwing Marion Kauffman Foundation Research Paper Series
-
Michael Ward, D. Dranove (1995)
THE VERTICAL CHAIN OF RESEARCH AND DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRYEconomic Inquiry, 33
-
J. Kao (2019)
Charted Territory: Evidence from Mapping the Cancer Genome and R & D Decisions in the Pharmaceutical Industry -
M. Kyle, A. McGahan (2009)
Investments in Pharmaceuticals Before and After TRIPSReview of Economics and Statistics, 94
-
Joshua Krieger, Danielle Li, D. Papanikolaou (2018)
Missing Novelty in Drug DevelopmentEwing Marion Kauffman Foundation Research Paper Series
-
Heidi Ledford (2010)
Rare victory in fight against melanomaNature, 467
-
P. Ascierto, J. Kirkwood, J. Grob, E. Simeone, A. Grimaldi, M. Maio, G. Palmieri, A. Testori, F. Marincola, N. Mozzillo (2012)
The role of BRAF V600 mutation in melanomaJournal of Translational Medicine, 10
-
Michael Hay, David Thomas, J. Craighead, Celia Economides, Jesse Rosenthal (2014)
Clinical development success rates for investigational drugsNature Biotechnology, 32
-
H. Grabowski, J. Vernon (2012)
The Distribution of Sales Revenues from Pharmaceutical InnovationPharmacoEconomics, 18
-
(2004)
The Pros and Cons of Importing Drugs from Canada -
Michael Lanthier, K. Miller, C. Nardinelli, J. Woodcock (2013)
An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011.Health affairs, 32 8
-
Subash Gupta, Bokyung Sung, S. Prasad, Lauren Webb, B. Aggarwal (2013)
Cancer drug discovery by repurposing: teaching new tricks to old dogs.Trends in pharmacological sciences, 34 9
-
Gary Engelhardt, J. Gruber (2010)
Medicare Part D and the Financial Protection of the ElderlyHEN: Public (Topic)
-
Jonathan Ketcham, K. Simon (2008)
Medicare Part D's effects on elderly patients' drug costs and utilization.The American journal of managed care, 14 11 Suppl
-
G. Zimmermann, J. Lehár, Curtis Keith (2007)
Multi-target therapeutics: when the whole is greater than the sum of the parts.Drug discovery today, 12 1-2
-
Bronwyn Hall, A. Jaffe, M. Trajtenberg (2005)
Market value and patent citationsThe RAND Journal of Economics, 36
-
J. Tobert (2003)
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitorsNature Reviews Drug Discovery, 2
-
M. Duggan, Fiona Morton (2008)
The Effect of Medicare Part D on Pharmaceutical Prices and UtilizationPublic Economics: National Government Expenditures & Related Policies eJournal
-
H. Shih, Xiaodan Zhang, A. Aronov (2017)
Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indicationsNature Reviews Drug Discovery, 17
-
A. Kesselheim, Bo-Sheng Wang, J. Avorn (2013)
Defining “Innovativeness” in Drug Development: A Systematic ReviewClinical Pharmacology & Therapeutics, 94
-
Joshua Krieger, Xuelin Li, Richard Thakor (2018)
Find and Replace: R&D Investment Following the Erosion of Existing ProductsCGN: Investment in R&D & Innovation (Topic)
-
H. Grabowski, J. Vernon, J. DiMasi (2012)
Returns on Research and Development for 1990s New Drug IntroductionsPharmacoEconomics, 20
-
B. Roth, D. Sheffler, W. Kroeze (2004)
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophreniaNature Reviews Drug Discovery, 3
-
H. Grabowski, J. Vernon (1990)
A New Look at the Returns and Risks to Pharmaceutical R&DManagement Science, 36
-
Fabian Gaessler, Stefan Wagner (2018)
Patents, Data Exclusivity, and the Development of New DrugsReview of Economics and Statistics, 104
-
Lindsay Shelledy, D. Román (2015)
Vemurafenib: First-in-Class BRAF-Mutated Inhibitor for the Treatment of Unresectable or Metastatic MelanomaJournal of the Advanced Practitioner in Oncology, 6
-
A. Gelijns, Nathan Rosenberg, Alan Moskowitz (1998)
Capturing the unexpected benefits of medical research.The New England journal of medicine, 339 10
-
I. Cockburn (2004)
The changing structure of the pharmaceutical industry.Health affairs, 23 1
-
M.A. Meyers (2007)
Happy Accidents: Serendipity in Modern Medical Breakthroughs -
C. Zheng, Lianyi Han, C. Yap, B. Xie, Yuzong Chen (2006)
Progress and problems in the exploration of therapeutic targets.Drug discovery today, 11 9-10
-
The, Quarterly of, May 1998 (2009)
Recombinant Growth -
F. Sams-Dodd (2005)
Target-based drug discovery: is something wrong?Drug discovery today, 10 2
-
Margaret Blume-Kohout, N. Sood (2013)
Market Size and Innovation: Effects of Medicare Part D on Pharmaceutical Research and Development.Journal of public economics, 97
-
G. Giovannetti, G. Jaggi, S. Bialojan (2012)
Beyond bordErs: Global Biotechnology Report 2012 -
Manuel Hermosilla (2019)
Rushed Innovation: Evidence from Drug LicensingERN: Innovation (Topic)
-
Wesley Yin, A. Basu, James Zhang, A. Rabbani, D. Meltzer, G. Alexander (2008)
The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and ExpendituresAnnals of Internal Medicine, 148
- Publisher
- Wiley
- Copyright
- © 2022 The RAND Corporation.
- ISSN
- 0741-6261
- eISSN
- 1756-2171
- DOI
- 10.1111/1756-2171.12422
- Publisher site
- See Article on Publisher Site
Abstract
Prior literature shows that stronger consumer demand leads to increased pharmaceutical R&D. However, how strong these “demand‐pull” effects are for more scientifically novel drug innovation remains unknown. We address this question using comprehensive clinical trial data that include precise characterizations of the scientific approaches used in tested molecules. We characterize scientific novelty as the number of times each approach has been used in the past. Exploiting exogenous demand variation introduced by the introduction of Medicare Part D, we find strong evidence that demand‐pull effects are markedly skewed in favor of non‐novel or “follow‐on” drug R&D.
Journal
The Rand Journal of Economics – Wiley
Published: Sep 1, 2022